Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.090
-0.050 (-4.39%)
At close: Apr 25, 2025, 4:00 PM
1.100
+0.010 (0.92%)
After-hours: Apr 25, 2025, 5:03 PM EDT
PACB Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for PACB stock have an average target of 2.45, with a low estimate of 1.50 and a high estimate of 4.00. The average target predicts an increase of 124.77% from the current stock price of 1.09.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PACB stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
Buy | 4 | 4 | 4 | 4 | 4 | 3 |
Hold | 8 | 8 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 15 | 15 | 13 | 13 | 13 | 11 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $3 | Strong Buy | Maintains | $3 | +175.23% | Apr 10, 2025 |
Scotiabank | Scotiabank | Buy Maintains $6 → $2 | Buy | Maintains | $6 → $2 | +83.49% | Mar 25, 2025 |
Piper Sandler | Piper Sandler | Hold Reiterates $2.5 → $2 | Hold | Reiterates | $2.5 → $2 | +83.49% | Feb 20, 2025 |
Goldman Sachs | Goldman Sachs | Hold Maintains $1.75 → $1.5 | Hold | Maintains | $1.75 → $1.5 | +37.61% | Feb 18, 2025 |
Stephens & Co. | Stephens & Co. | Buy Reiterates $2.5 | Buy | Reiterates | $2.5 | +129.36% | Feb 18, 2025 |
Financial Forecast
Revenue This Year
164.04M
from 154.01M
Increased by 6.51%
Revenue Next Year
203.02M
from 164.04M
Increased by 23.76%
EPS This Year
-0.73
from -1.13
EPS Next Year
-0.61
from -0.73
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 173.2M | 250.4M | 306.6M | ||
Avg | 164.0M | 203.0M | 249.8M | ||
Low | 152.0M | 177.4M | 199.9M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 12.4% | 52.7% | 51.0% | ||
Avg | 6.5% | 23.8% | 23.1% | ||
Low | -1.3% | 8.1% | -1.5% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.68 | -0.32 | -0.19 | ||
Avg | -0.73 | -0.61 | -0.48 | ||
Low | -0.76 | -0.69 | -0.57 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.